- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Regenxbio Inc (RGNX)
Regenxbio Inc stock price live, this page displays NASDAQ RGNX stock exchange data. View the RGNX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Regenxbio Inc real time stock price chart below.
What Is the Regenxbio Inc Stock Price Today?
The Regenxbio Inc stock price today is 9.00.
What Is the Stock Symbol for Regenxbio Inc?
The stock symbol for Regenxbio Inc is "RGNX."
What Stock Exchange Does Regenxbio Inc Trade On?
Regenxbio Inc is listed and trades on the NASDAQ stock exchange.
Is Regenxbio Inc a Good Stock to Buy?
Determining whether Regenxbio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGNX quote. (ISIN: US75901B1070)
What Is the Regenxbio Inc Stock Price Today?
The Regenxbio Inc stock price today is 9.00.
What Is the Stock Symbol for Regenxbio Inc?
The stock symbol for Regenxbio Inc is "RGNX."
What Stock Exchange Does Regenxbio Inc Trade On?
Regenxbio Inc is listed and trades on the NASDAQ stock exchange.
Is Regenxbio Inc a Good Stock to Buy?
Determining whether Regenxbio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGNX quote. (ISIN: US75901B1070)
9.00
+0.13(+1.47%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.52
9.05
52 wk Range
5.04
17.52
RGNX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 6 days
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.529.05
52 wk Range
5.0417.52
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RGNX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
32.50
Upside
+261.11%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Regenxbio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Regenxbio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Regenxbio Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Regenxbio Inc Company Profile
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Regenxbio Inc SWOT Analysis
Gene Therapy Pionee | REGENXBIO's innovative pipeline targets genetic and rare diseases, with promising developments in DMD and ocular therapies positioning it for potential market leadership |
Financial Prospects | Analysts project stock upside with price targets ranging from $18 to $52, despite current market challenges and negative near-term EPS estimates |
Competitive Edge | Explore REGENXBIO's differentiated DMD treatment, addressing limitations of existing therapies and potentially capturing a significant share of the $3 billion market |
Strategic Catalysts | Upcoming milestones include potential $200M payment for DR trial initiation and BLA submissions, with opportunities for accelerated regulatory pathways |
Regenxbio Inc Earnings Call Summary for Q4/2024
- Q4 2024 EPS beats forecast at -1.01 vs -1.13; revenue misses at $21.21M vs $23.47M expected
- Stock surges 4.73% in aftermarket trading to $6.86; analysts set price targets from $14 to $52
- Strong cash position of $245M; R&D expenses down to $209M in 2024 from $232M in 2023
- BLA submission for RGX-121 (Hunter Syndrome); FDA approval expected Q4 2025
- CEO highlights 2025 as transformational year; multiple gene therapy launches planned for 2026-2027
Last Updated: 14/03/2025, 09:00 am
Read Full TranscriptCompare RGNX to Peers and Sector
Metrics to compare | RGNX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRGNXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.9x | −3.6x | −0.5x | |
PEG Ratio | −0.08 | −0.09 | 0.00 | |
Price/Book | 1.7x | 2.1x | 2.6x | |
Price / LTM Sales | 5.3x | 10.4x | 2.9x | |
Upside (Analyst Target) | 249.6% | 245.4% | 57.2% | |
Fair Value Upside | Unlock | 9.5% | 8.9% | Unlock |
Analyst Ratings
11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 32.50
(+261.11% Upside)
Earnings
Latest Release
Mar 13, 2025
EPS / Forecast
-1.01 / -1.13
Revenue / Forecast
21.21M / 23.47M
People Also Watch
FAQ
What Is the Regenxbio Inc (RGNX) Stock Price Today?
The Regenxbio Inc stock price today is 9.00
What Stock Exchange Does Regenxbio Inc Trade On?
Regenxbio Inc is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Regenxbio Inc?
The stock symbol for Regenxbio Inc is "RGNX."
What Is the Regenxbio Inc Market Cap?
As of today, Regenxbio Inc market cap is 441.53M.
What is Regenxbio Inc Earnings Per Share?
The Regenxbio Inc EPS is -4.59.
What Is the Next Regenxbio Inc Earnings Date?
Regenxbio Inc will release its next earnings report on 29 Apr 2025.
From a Technical Analysis Perspective, Is RGNX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.